On June 5, 2026 Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, reported that management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. With an initial focus in oncology, Foghorn’s Gene Traffic Control platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Goldman Sachs 47th Annual Global Healthcare Conference 2026
Fireside Chat: Tuesday, June 9, 2026, at 1:20 p.m. EDT
Presenter: Adrian Gottschalk, President and Chief Executive Officer
Registration link: Register here
Management will also participate in one-on-one meetings
A webcast of the fireside chat can be accessed under "Events & Presentations" in the Investors section of the Company’s website here and will be available for 90 days.
(Press release, Foghorn Therapeutics, JUN 5, 2026, View Source [SID1234666471])